We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Masimo (MASI) Beats on Q1 Earnings and Revenues, Guides Up
Read MoreHide Full Article
Masimo Corp. (MASI - Free Report) reported earnings of 57 cents per share in the first quarter of 2017 outperforming the Zacks Consensus Estimate of 54 cents. The bottom line also improved from the year-ago earnings of 53 cents.
Revenues improved 8.8% to $186.3 million from $171.2 million in the year-ago quarter and beat the Zacks Consensus Estimate of $184.0 million.
Stock Performance
Year to date, Masimo’s shares have increased roughly 26.32%, comparing favorably with the Zacks categorized Medical Instruments’ sub-industry’s addition of 12.97%. The current level is higher than the S&P 500’s return of 8.88% in the same time frame.
Quarter Details
Worldwide direct product revenues (87.0% of product revenue) increased 9.9% to $178.1 million. OEM sales (13.0% of product revenues) rose 3.7% to $23.2 million from the year-ago quarter. Total U.S. product revenue increased 9.8% to $124.7 million on a year-over-year basis.
The company’s Rainbow product revenues in the reported quarter totaled $13.9 million, which was down 17.8% on a year-over-year basis. Meanwhile, total hemoglobin revenues were $2.8 million in the quarter, down from $6.1 million in the prior-year period. However, Masimo witnessed a 30% gain in the sales of U.S. single-use rainbow adhesive sensors on a year-over-year basis.
During the reported quarter, the company shipped approximately 47,900 SET Pulse Oximeters and Rainbow SET Pulse CO-Oximeters, excluding handheld units. Per company estimation, its worldwide installed base was 1,525,000 units, up 6.1% from 1,438,000 units as of Apr 2, 2016.
Masimo Corporation Price, Consensus and EPS Surprise
As of Apr 1, 2017, Masimo’s total cash and cash investments were $343.8 million compared with $306 million as of Dec 31, 2016. The company generated $15.4 million in cash from operations and received $27.3 million in proceeds from stock option exercises.
Guidance
Masimo now expects total fiscal 2017 revenues of approximately $759.0 million, up from the previously provided guidance of $752.0 million. Total fiscal 2017 product revenues are projected at approximately $727.0 million, up from the previous guidance of $721.0 million. Royalty revenues projections increased to approximately $32.0 million from the previously provided guidance of $31.0 million. Fiscal 2017 earnings per diluted share are expected to be approximately $2.65, up from $2.30.
Regeneron Pharmaceuticals has increased 18% in the last one year, compared with the S&P 500’s 16.0% gain. It has a trailing four-quarter average positive earnings surprise of 0.45%.
Bio-Rad Laboratories has surged 55.7% in the past one year, better than the S&P 500 mark. It has a four-quarter average earnings surprise of 13.10%.
Baxter International has returned 23.1% in the last one year in comparison to the S&P 500. It has a four-quarter average positive earnings surprise of 17.14%.
Sell These Stocks.Now.
Just released, today's 220 Zacks Rank #5 Strong Sells demand urgent attention. If any are lurking in your portfolio or Watch List, they should be removed immediately. These are sinister companies because many appear to be sound investments. However, from 1988 through 2016, stocks from our Strong Sell list have actually performed 6X worse than the S&P 500. See today's Zacks "Strong Sells" absolutely free >>
See More Zacks Research for These Tickers
Pick one free report - opportunity may be withdrawn at any time
Image: Bigstock
Masimo (MASI) Beats on Q1 Earnings and Revenues, Guides Up
Masimo Corp. (MASI - Free Report) reported earnings of 57 cents per share in the first quarter of 2017 outperforming the Zacks Consensus Estimate of 54 cents. The bottom line also improved from the year-ago earnings of 53 cents.
Revenues improved 8.8% to $186.3 million from $171.2 million in the year-ago quarter and beat the Zacks Consensus Estimate of $184.0 million.
Stock Performance
Year to date, Masimo’s shares have increased roughly 26.32%, comparing favorably with the Zacks categorized Medical Instruments’ sub-industry’s addition of 12.97%. The current level is higher than the S&P 500’s return of 8.88% in the same time frame.
Quarter Details
Worldwide direct product revenues (87.0% of product revenue) increased 9.9% to $178.1 million. OEM sales (13.0% of product revenues) rose 3.7% to $23.2 million from the year-ago quarter. Total U.S. product revenue increased 9.8% to $124.7 million on a year-over-year basis.
The company’s Rainbow product revenues in the reported quarter totaled $13.9 million, which was down 17.8% on a year-over-year basis. Meanwhile, total hemoglobin revenues were $2.8 million in the quarter, down from $6.1 million in the prior-year period. However, Masimo witnessed a 30% gain in the sales of U.S. single-use rainbow adhesive sensors on a year-over-year basis.
During the reported quarter, the company shipped approximately 47,900 SET Pulse Oximeters and Rainbow SET Pulse CO-Oximeters, excluding handheld units. Per company estimation, its worldwide installed base was 1,525,000 units, up 6.1% from 1,438,000 units as of Apr 2, 2016.
Masimo Corporation Price, Consensus and EPS Surprise
Masimo Corporation Price, Consensus and EPS Surprise | Masimo Corporation Quote
Financial Condition
As of Apr 1, 2017, Masimo’s total cash and cash investments were $343.8 million compared with $306 million as of Dec 31, 2016. The company generated $15.4 million in cash from operations and received $27.3 million in proceeds from stock option exercises.
Guidance
Masimo now expects total fiscal 2017 revenues of approximately $759.0 million, up from the previously provided guidance of $752.0 million. Total fiscal 2017 product revenues are projected at approximately $727.0 million, up from the previous guidance of $721.0 million. Royalty revenues projections increased to approximately $32.0 million from the previously provided guidance of $31.0 million. Fiscal 2017 earnings per diluted share are expected to be approximately $2.65, up from $2.30.
Zacks Rank & Stocks to Consider
Masimo has a Zacks Rank #3 (Hold).
Better-ranked medical stocks include Regeneron Pharmaceuticals, Inc. (REGN - Free Report) , Bio-Rad Laboratories, Inc. (BIO - Free Report) and Baxter International Inc. (BAX - Free Report) . Regeneron Pharmaceuticals and Bio-Rad Laboratories sport a Zacks Rank #1 (Strong Buy), while Baxter International carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 (Strong Buy) Rank stocks here.
Regeneron Pharmaceuticals has increased 18% in the last one year, compared with the S&P 500’s 16.0% gain. It has a trailing four-quarter average positive earnings surprise of 0.45%.
Bio-Rad Laboratories has surged 55.7% in the past one year, better than the S&P 500 mark. It has a four-quarter average earnings surprise of 13.10%.
Baxter International has returned 23.1% in the last one year in comparison to the S&P 500. It has a four-quarter average positive earnings surprise of 17.14%.
Sell These Stocks. Now.
Just released, today's 220 Zacks Rank #5 Strong Sells demand urgent attention. If any are lurking in your portfolio or Watch List, they should be removed immediately. These are sinister companies because many appear to be sound investments. However, from 1988 through 2016, stocks from our Strong Sell list have actually performed 6X worse than the S&P 500. See today's Zacks "Strong Sells" absolutely free >>